fbpx
Wikipedia

Riamilovir

April 13, 2024

Riamilovir is a broad-spectrum antiviral drug developed in Russia through a joint effort of Ural Federal University, Russian Academy of Sciences, Ural Center for Biopharma Technologies and Medsintez Pharmaceutical.[1] It has a novel triazolotriazine core, which represents a new structural class of non-nucleoside antiviral drugs.[2]

Riamilovir
Clinical data
Other namesTZV, Triazavirin
ATC code
  • None
Identifiers
  • 2-methylsulfanyl-6-nitro[1,2,4]triazolo[5,1-c] [1,2,4]triazin-7(4H)-one
CAS Number
  • 123606-06-4
  • Sodium salt: 928659-17-0
PubChem CID
  • 3113817
DrugBank
  • DB15622
ChemSpider
  • 2367718
UNII
  • F2HTG1MH2D
  • Sodium salt: G1JE34QF2S
ChEMBL
  • ChEMBL1618116
CompTox Dashboard (EPA)
  • DTXSID40389402
ECHA InfoCard100.217.074
Chemical and physical data
FormulaC5H4N6O3S
Molar mass228.19 g·mol−1
3D model (JSmol)
  • Interactive image
  • CSc1[nH]n2c(=O)c(nnc2n1)[N+](=O)[O-]
  • InChI=1S/C5H4N6O3S/c1-15-5-6-4-8-7-2(11(13)14)3(12)10(4)9-5/h1H3,(H,6,8,9)
  • Key:IDVQGNMSSHPZSJ-UHFFFAOYSA-N

The main principle action of triazavirin is to inhibit the synthesis of viral ribonucleic acid (RNA) and the replication of viral genomic fragments through its synthetic analogue to the bases of purine nucleosides.[3][4][5]

Uses edit

It was originally developed as a potential treatment for pandemic influenza strains such as H5N1, and most of the testing that has been done has focused on its anti-influenza activity.[5][3][6][7][8] However, triazavirin has also been found to have antiviral activity against a number of other viruses including tick-borne encephalitis virus,[4][9] and is also being investigated for potential application against a lethal influenza infection and secondary bacterial pneumonia following influenza,[10] Lassa fever and Ebola virus disease.[11][12][13][14][15] Triazavirin has passed clinical trials and has shown antiviral activity against ARVI.[16][17][18][19] In 2020, testing of triazavirin was started against SARS-CoV-2 in Russia, China, and South Africa. [20][21][22][23][24][25][excessive citations] The mechanism of action of Triazavirin is still controversial. No experimental biochemical studies on the activity of Triazavirin relating to SARS-CoV-2 or influenza target proteins have so far been published.[26]

In August 2014, the Ministry of Health of Russia issued a registration certificate for triazavirin.[27] The active substance of the drug triazavirin is a new active molecule,[2] and can be dispensed by prescription. The production of triazavirin is carried out at a modern pharmaceutical enterprise LLC "Plant Medsintez".[1] The registration procedure for triazavirin has begun in the Republic of South Africa.[24]

Criticism edit

The studies of Triazavirin were non-blinded and non-randomized, and included 66 patients only with, with 44 in a control group.[16]

References edit

  1. ^ a b "Triazaverin Is Officially Recommended". www.medsintez.com. Retrieved 2021-02-25.
  2. ^ a b Rusinov VL, Sapozhnikova IM, Ulomskii EN, Medvedeva NR, Egorov VV, Kiselev OI, et al. (2015). "Nucleophilic substitution of nitro group in nitrotriazolotriazines as a model of potential interaction with cysteine-containing proteins". Chemistry of Heterocyclic Compounds. 51 (3): 275–280. doi:10.1007/s10593-015-1695-4. S2CID 83702396.
  3. ^ a b Karpenko I, Deev S, Kiselev O, Charushin V, Rusinov V, Ulomsky E, et al. (May 2010). "Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication". Antimicrobial Agents and Chemotherapy. 54 (5): 2017–2022. doi:10.1128/AAC.01186-09. PMC 2863629. PMID 20194696.
  4. ^ a b Loginova SI, Borisevich SV, Rusinov VL, Ulomskiĭ UN, Charushin VN, Chupakhin ON (2014). "[Investigation of Triazavirin antiviral activity against tick-borne encephalitis pathogen in cell culture]". Antibiotiki i Khimioterapiia (in Russian). 59 (1–2): 3–5. PMID 25051708.
  5. ^ a b Loginova SI, Borisevich SV, Maksimov VA, Bondarev VP, Kotovskaia SK, Rusinov VL, et al. (2007). "[Investigation of triazavirin antiviral activity against influenza A virus (H5N1) in cell culture]". Antibiotiki i Khimioterapiia (in Russian). 52 (11–12): 18–20. PMID 19275052.
  6. ^ Kiselev OI, Deeva EG, Mel'nikova TI, Kozeletskaia KN, Kiselev AS, Rusinov VL, et al. (2012). "[A new antiviral drug Triazavirin: results of phase II clinical trial]". Voprosy Virusologii (in Russian). 57 (6): 9–12. PMID 23477247.
  7. ^ Kasianenko KV, Lvov NI, Maltsev OV, Zhdanov KV (9 October 2019). "Nucleoside analogues for the treatment of influenza: History and experience". Journal of Infectology (in Russian). 11 (3): 20–26. doi:10.22625/2072-6732-2019-11-3-20-26. S2CID 241604614.
  8. ^ Sologub TV, Tokin II, Midikari AS, Tsvetkov VV (2017). "A comparative efficacy and safety of using antiviral drugs in therapy of patients with influenza". Infekcionnye Bolezni (in Russian). 15 (3): 25–32. doi:10.20953/1729-9225-2017-3-25-32.
  9. ^ Loginova SY, Borisevich SV, Rusinov VL, Ulomsky EN, Charushin VN, Chupakhin ON, et al. (2015). "[Investigation of Therapeutic Efficacy of Triazavirin Against Experimental Forest-Spring Encephalitis on Albino Mice]". Antibiotiki i Khimioterapiia (in Russian). 60 (7–8): 11–13. PMID 26863736.
  10. ^ Leneva IA, Falynskova IN, Makhmudova NR, Glubokova EA, Kartashova NP, Leonova EI, et al. (2018-02-22). "Effect of triazavirine on the outcome of a lethal influenza infection and secondary bacterial pneumonia following influenza in mice". Microbiology Independent Research Journal. 4 (1). doi:10.18527/2500-2236-2017-4-1-52-57.
  11. ^ "Target: Ebola". Pravda. 2014-12-22. Retrieved 18 January 2015.
  12. ^ . Yekaterinburg News Reports. 6 January 2015. Archived from the original on 18 January 2015. Retrieved 18 January 2015.
  13. ^ Cox S (2014-10-17). "Ebola crisis: Vaccine 'too late' for outbreak. BBC News, 17 October 2014". BBC News.
  14. ^ Bora K (12 November 2014). "Russia Will Begin Testing Triazavirin, Used For Lassa Fever, And Other Drugs On Ebola: Health Ministry". International Business Times.
  15. ^ Kezina D (12 November 2014). "New antiviral drug from Urals will help fight Ebola and other viruses". Russia Beyond the Headlines.
  16. ^ a b Tikhonova EP, Kuz'mina TY, Andronova NV, Tyushevskaya OA, Elistratova TA, Kuz'min AE (2018-04-15). "Study of effectiveness of antiviral drugs (umifenovir, triazavirin) against acute respiratory viral infections". Kazan Medical Journal (in Russian). 99 (2): 215–223. doi:10.17816/KMJ2018-215. ISSN 2587-9359.
  17. ^ Verevshchikov VK, Shemyakina EK, Sabitov AU, Khamanova YB (2019). "The Possibilities of Etiotropic Therapy for Influenza and ARVI with Taking into Account the Period of Hospitalization and the Risk of Developing Secondary Complications". Antibiotics and Chemotherapy. Retrieved 2021-02-25.
  18. ^ Lioznov DA, Tokin II, Zubkova TG, Sorokin PV (December 2020). "[The practice of using a domestic antiviral drug in the etiotropic therapy of acute respiratory viral infection]". Terapevticheskii Arkhiv (in Russian). 92 (12): 160–164. doi:10.26442/00403660.2020.12.200427. PMID 33720589.
  19. ^ Verevshchikov VK, Shemyakina EK, Sabitov AU, Batskalevich NA (2018). "Modern Etiotropic Therapy of Influenza and ARVI in Adult Patients with Premorbid Pathology". Antibiotics and Chemotherapy. Retrieved 2021-02-25.
  20. ^ Jamshaid U (4 February 2020). "China Testing Russia's Triazavirin As Coronavirus Treatment". Russian Health Ministry. Urdupoint.
  21. ^ Phiri C (5 February 2020). . Zambia Reports. Archived from the original on 5 February 2020. Retrieved 11 February 2020.
  22. ^ Wu X, Yu K, Wang Y, Xu W, Ma H, Hou Y, et al. (October 2020). "Efficacy and Safety of Triazavirin Therapy for Coronavirus Disease 2019: A Pilot Randomized Controlled Trial". Engineering. 6 (10): 1185–1191. doi:10.1016/j.eng.2020.08.011. PMC 7476906. PMID 32923016. S2CID 221520816.
  23. ^ Brandt K. "SA study to trial antiviral Triazavirin as COVID-19 treatment". ewn.co.za. Retrieved 2021-02-25.
  24. ^ a b "Discussion on Russia's antiviral drug Triazavirin". SABC News. 21 January 2021 – via YouTube.
  25. ^ Sabitov AU, Belousov VV, Edin AS, Oleinichenko EV, Gladunova EP, Tikhonova EP, et al. (21 November 2020). "Practical Experience of Using Riamilovir in Treatment of Patients with Moderate COVID-19". Antibiotiki i Khimioterapiya. 65 (7–8): 27–30. doi:10.37489/0235-2990-2020-65-7-8-27-30. S2CID 229508119.
  26. ^ Chupakhin ON, Rusinov VL, Varaksin MV, Ulomskiy EN, Savateev KV, Butorin II, et al. (November 2022). "Triazavirin-A Novel Effective Antiviral Drug". International Journal of Molecular Sciences. 23 (23): 14537. doi:10.3390/ijms232314537. PMC 9738222. PMID 36498864.
  27. ^ "Triazavirin (Riamilovir)". State Register of Medicines of the Russian Federation (in Russian).


 

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

April 13, 2024
riamilovir, broad, spectrum, antiviral, drug, developed, russia, through, joint, effort, ural, federal, university, russian, academy, sciences, ural, center, biopharma, technologies, medsintez, pharmaceutical, novel, triazolotriazine, core, which, represents, . Riamilovir is a broad spectrum antiviral drug developed in Russia through a joint effort of Ural Federal University Russian Academy of Sciences Ural Center for Biopharma Technologies and Medsintez Pharmaceutical 1 It has a novel triazolotriazine core which represents a new structural class of non nucleoside antiviral drugs 2 RiamilovirClinical dataOther namesTZV TriazavirinATC codeNoneIdentifiersIUPAC name 2 methylsulfanyl 6 nitro 1 2 4 triazolo 5 1 c 1 2 4 triazin 7 4H oneCAS Number123606 06 4Sodium salt 928659 17 0PubChem CID3113817DrugBankDB15622ChemSpider2367718UNIIF2HTG1MH2DSodium salt G1JE34QF2SChEMBLChEMBL1618116CompTox Dashboard EPA DTXSID40389402ECHA InfoCard100 217 074Chemical and physical dataFormulaC 5H 4N 6O 3SMolar mass228 19 g mol 13D model JSmol Interactive imageSMILES CSc1 nH n2c O c nnc2n1 N O O InChI InChI 1S C5H4N6O3S c1 15 5 6 4 8 7 2 11 13 14 3 12 10 4 9 5 h1H3 H 6 8 9 Key IDVQGNMSSHPZSJ UHFFFAOYSA NThe main principle action of triazavirin is to inhibit the synthesis of viral ribonucleic acid RNA and the replication of viral genomic fragments through its synthetic analogue to the bases of purine nucleosides 3 4 5 Uses editIt was originally developed as a potential treatment for pandemic influenza strains such as H5N1 and most of the testing that has been done has focused on its anti influenza activity 5 3 6 7 8 However triazavirin has also been found to have antiviral activity against a number of other viruses including tick borne encephalitis virus 4 9 and is also being investigated for potential application against a lethal influenza infection and secondary bacterial pneumonia following influenza 10 Lassa fever and Ebola virus disease 11 12 13 14 15 Triazavirin has passed clinical trials and has shown antiviral activity against ARVI 16 17 18 19 In 2020 testing of triazavirin was started against SARS CoV 2 in Russia China and South Africa 20 21 22 23 24 25 excessive citations The mechanism of action of Triazavirin is still controversial No experimental biochemical studies on the activity of Triazavirin relating to SARS CoV 2 or influenza target proteins have so far been published 26 In August 2014 the Ministry of Health of Russia issued a registration certificate for triazavirin 27 The active substance of the drug triazavirin is a new active molecule 2 and can be dispensed by prescription The production of triazavirin is carried out at a modern pharmaceutical enterprise LLC Plant Medsintez 1 The registration procedure for triazavirin has begun in the Republic of South Africa 24 Criticism editThe studies of Triazavirin were non blinded and non randomized and included 66 patients only with with 44 in a control group 16 References edit a b Triazaverin Is Officially Recommended www medsintez com Retrieved 2021 02 25 a b Rusinov VL Sapozhnikova IM Ulomskii EN Medvedeva NR Egorov VV Kiselev OI et al 2015 Nucleophilic substitution of nitro group in nitrotriazolotriazines as a model of potential interaction with cysteine containing proteins Chemistry of Heterocyclic Compounds 51 3 275 280 doi 10 1007 s10593 015 1695 4 S2CID 83702396 a b Karpenko I Deev S Kiselev O Charushin V Rusinov V Ulomsky E et al May 2010 Antiviral properties metabolism and pharmacokinetics of a novel azolo 1 2 4 triazine derived inhibitor of influenza A and B virus replication Antimicrobial Agents and Chemotherapy 54 5 2017 2022 doi 10 1128 AAC 01186 09 PMC 2863629 PMID 20194696 a b Loginova SI Borisevich SV Rusinov VL Ulomskiĭ UN Charushin VN Chupakhin ON 2014 Investigation of Triazavirin antiviral activity against tick borne encephalitis pathogen in cell culture Antibiotiki i Khimioterapiia in Russian 59 1 2 3 5 PMID 25051708 a b Loginova SI Borisevich SV Maksimov VA Bondarev VP Kotovskaia SK Rusinov VL et al 2007 Investigation of triazavirin antiviral activity against influenza A virus H5N1 in cell culture Antibiotiki i Khimioterapiia in Russian 52 11 12 18 20 PMID 19275052 Kiselev OI Deeva EG Mel nikova TI Kozeletskaia KN Kiselev AS Rusinov VL et al 2012 A new antiviral drug Triazavirin results of phase II clinical trial Voprosy Virusologii in Russian 57 6 9 12 PMID 23477247 Kasianenko KV Lvov NI Maltsev OV Zhdanov KV 9 October 2019 Nucleoside analogues for the treatment of influenza History and experience Journal of Infectology in Russian 11 3 20 26 doi 10 22625 2072 6732 2019 11 3 20 26 S2CID 241604614 Sologub TV Tokin II Midikari AS Tsvetkov VV 2017 A comparative efficacy and safety of using antiviral drugs in therapy of patients with influenza Infekcionnye Bolezni in Russian 15 3 25 32 doi 10 20953 1729 9225 2017 3 25 32 Loginova SY Borisevich SV Rusinov VL Ulomsky EN Charushin VN Chupakhin ON et al 2015 Investigation of Therapeutic Efficacy of Triazavirin Against Experimental Forest Spring Encephalitis on Albino Mice Antibiotiki i Khimioterapiia in Russian 60 7 8 11 13 PMID 26863736 Leneva IA Falynskova IN Makhmudova NR Glubokova EA Kartashova NP Leonova EI et al 2018 02 22 Effect of triazavirine on the outcome of a lethal influenza infection and secondary bacterial pneumonia following influenza in mice Microbiology Independent Research Journal 4 1 doi 10 18527 2500 2236 2017 4 1 52 57 Target Ebola Pravda 2014 12 22 Retrieved 18 January 2015 Yekaterinburg pharmacies to sell domestic antiviral drug Yekaterinburg News Reports 6 January 2015 Archived from the original on 18 January 2015 Retrieved 18 January 2015 Cox S 2014 10 17 Ebola crisis Vaccine too late for outbreak BBC News 17 October 2014 BBC News Bora K 12 November 2014 Russia Will Begin Testing Triazavirin Used For Lassa Fever And Other Drugs On Ebola Health Ministry International Business Times Kezina D 12 November 2014 New antiviral drug from Urals will help fight Ebola and other viruses Russia Beyond the Headlines a b Tikhonova EP Kuz mina TY Andronova NV Tyushevskaya OA Elistratova TA Kuz min AE 2018 04 15 Study of effectiveness of antiviral drugs umifenovir triazavirin against acute respiratory viral infections Kazan Medical Journal in Russian 99 2 215 223 doi 10 17816 KMJ2018 215 ISSN 2587 9359 Verevshchikov VK Shemyakina EK Sabitov AU Khamanova YB 2019 The Possibilities of Etiotropic Therapy for Influenza and ARVI with Taking into Account the Period of Hospitalization and the Risk of Developing Secondary Complications Antibiotics and Chemotherapy Retrieved 2021 02 25 Lioznov DA Tokin II Zubkova TG Sorokin PV December 2020 The practice of using a domestic antiviral drug in the etiotropic therapy of acute respiratory viral infection Terapevticheskii Arkhiv in Russian 92 12 160 164 doi 10 26442 00403660 2020 12 200427 PMID 33720589 Verevshchikov VK Shemyakina EK Sabitov AU Batskalevich NA 2018 Modern Etiotropic Therapy of Influenza and ARVI in Adult Patients with Premorbid Pathology Antibiotics and Chemotherapy Retrieved 2021 02 25 Jamshaid U 4 February 2020 China Testing Russia s Triazavirin As Coronavirus Treatment Russian Health Ministry Urdupoint Phiri C 5 February 2020 China Tests Russian Antiviral Drug Which Might Treat Coronavirus As Moscow Warns Of Possible Mass Outbreak Zambia Reports Archived from the original on 5 February 2020 Retrieved 11 February 2020 Wu X Yu K Wang Y Xu W Ma H Hou Y et al October 2020 Efficacy and Safety of Triazavirin Therapy for Coronavirus Disease 2019 A Pilot Randomized Controlled Trial Engineering 6 10 1185 1191 doi 10 1016 j eng 2020 08 011 PMC 7476906 PMID 32923016 S2CID 221520816 Brandt K SA study to trial antiviral Triazavirin as COVID 19 treatment ewn co za Retrieved 2021 02 25 a b Discussion on Russia s antiviral drug Triazavirin SABC News 21 January 2021 via YouTube Sabitov AU Belousov VV Edin AS Oleinichenko EV Gladunova EP Tikhonova EP et al 21 November 2020 Practical Experience of Using Riamilovir in Treatment of Patients with Moderate COVID 19 Antibiotiki i Khimioterapiya 65 7 8 27 30 doi 10 37489 0235 2990 2020 65 7 8 27 30 S2CID 229508119 Chupakhin ON Rusinov VL Varaksin MV Ulomskiy EN Savateev KV Butorin II et al November 2022 Triazavirin A Novel Effective Antiviral Drug International Journal of Molecular Sciences 23 23 14537 doi 10 3390 ijms232314537 PMC 9738222 PMID 36498864 Triazavirin Riamilovir State Register of Medicines of the Russian Federation in Russian nbsp This antiinfective drug article is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Riamilovir amp oldid 1214492117, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.